[
  {
    "question": "Woman who is post-partum (gave birth through CS) presented with headache, MRI done is shown (coronal T1 with pachymeningeal enhancement) headache increase when she sits, what is the best management:",
    "option_a": "blood patch",
    "option_b": "MRV/MRI",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Post-dural puncture headache (PDPH) is a common complication following neuraxial anesthesia (epidural/spinal) during cesarean section. It is characterized by a positional headache (worse when standing, better when lying down) due to cerebrospinal fluid (CSF) leakage. The loss of CSF volume leads to a decrease in intracranial pressure, which in turn causes traction on pain-sensitive structures in the cranium. The resultant compensatory pachymeningeal enhancement on MRI is due to dilatation of the dural veins. Patients typically report a headache that worsens in the upright position and improves when supine. The MRI finding of pachymeningeal enhancement in the setting of these symptoms is highly suggestive of intracranial hypotension, most commonly due to CSF leak from a dural puncture. Diagnosis is primarily clinical. MRI is used to confirm the diagnosis if the clinical picture is ambiguous, showing diffuse pachymeningeal enhancement. It is crucial to differentiate PDPH from other causes of postpartum headache such as preeclampsia, migraine, or cerebral venous sinus thrombosis. First-line management for PDPH includes conservative treatments such as bed rest, hydration, and caffeine. However, if symptoms persist or are severe, an epidural blood patch (EBP) is indicated as it is both diagnostic and therapeutic. In postpartum patients, while considering the need for breastfeeding, the use of an EBP is generally safe; any medications used should be evaluated for excretion in breast milk. Option A (blood patch) is the best management option in a scenario where the headache is severe or refractory to conservative therapy, particularly given the classic MRI findings. Option B (MRV/MRI) would be more appropriate if the diagnosis was uncertain or if there was suspicion of cerebral venous sinus thrombosis, but the imaging here fits PDPH. 1. PDPH is characterized by positional headache that worsens with sitting/standing. 2. Pachymeningeal enhancement on MRI is virtually pathognomonic for intracranial hypotension. 3. An epidural blood patch is highly effective for treatment if conservative measures fail. Recent consensus guidelines support early intervention with an epidural blood patch for severe or persistent PDPH. Studies confirm its high success rate and safety profile in postpartum women, including those who are breastfeeding.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A boy who presented with early morning headache and suprasellar mass found on imaging with hormonal changes what is the most likely tumor:",
    "option_a": "genomic",
    "option_b": "medulloblastoma",
    "option_c": "germinoma",
    "option_d": "DNET",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Intracranial tumors in the suprasellar region can cause symptoms secondary to mass effect and disruption of endocrine pathways. In pediatric patients, common tumors in this region include germinomas and craniopharyngiomas. Germinomas are malignant germ cell tumors that tend to involve midline structures such as the pineal and suprasellar regions. Their growth can disrupt the hypothalamic-pituitary axis leading to hormonal imbalances. They may present with signs of increased intracranial pressure (such as early morning headache) and endocrine abnormalities. A boy presenting with early morning headaches (indicative of raised intracranial pressure) and hormonal changes is highly suggestive of a tumor affecting the suprasellar region. Germinomas often occur in adolescent males and can lead to diabetes insipidus, growth hormone deficiency, and other pituitary dysfunctions. Imaging studies (MRI/CT) are key. Germinomas typically appear as solid, homogeneous masses in the suprasellar region without the calcifications or cystic components more typical of craniopharyngiomas. Differential diagnoses include craniopharyngioma (usually with calcifications and cystic components), pituitary adenoma (rare in children), and hypothalamic glioma. Management involves a multidisciplinary approach. First-line treatment for intracranial germinomas typically includes radiotherapy often combined with chemotherapy to reduce tumor burden and improve control. In pediatric patients, treatment plans are tailored to minimize long-term neurocognitive and endocrinologic sequelae. Since this patient is a boy, pregnancy and lactation considerations are not applicable; however, in female patients in the reproductive age group, fertility preservation and hormonal management are considered. Option A ('genomic') does not represent a recognized tumor entity in this context. Option B (medulloblastoma) is typically a cerebellar tumor seen in the posterior fossa, not the suprasellar region. Option D (DNET) is usually associated with seizures and cortical lesions. Option C (germinoma) is the correct and most fitting diagnosis given the location, patient demographics, and endocrine dysfunction. 1. Suprasellar germinomas are common in adolescent males and frequently present with endocrine disturbances such as diabetes insipidus. 2. They are highly radiosensitive, which informs their therapeutic strategy. 3. Differentiation from craniopharyngiomas is key, as the management differs considerably. Current research emphasizes combined modality treatment with reduced doses of radiotherapy and chemotherapy to limit long-term side effects in pediatric populations. Guidelines continue to evolve to tailor treatment intensity based on tumor markers and imaging characteristics.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about hemicrania pt with continuous headache since 4 months and she have episodic increase in pain intensity what is rx:",
    "option_a": "Indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua is a primary headache disorder characterized by a continuous unilateral headache with superimposed exacerbations. A hallmark of this condition is its absolute responsiveness to indomethacin. Although the exact underlying mechanism of hemicrania continua isn\u2019t fully elucidated, it is believed to involve dysregulation in the trigeminal-autonomic pathways. The distinct response to indomethacin suggests a specific prostaglandin-mediated or inflammatory component that is effectively inhibited by this medication. Patients with hemicrania continua experience a persistent, unilateral headache that may fluctuate in intensity, with episodes of severe pain. Autonomic phenomena (such as tearing or nasal congestion) can accompany exacerbations. The complete response to indomethacin is both diagnostic and therapeutic. The diagnosis is primarily clinical based on history and the indomethacin trial. Differential diagnoses include cluster headache (which typically has discrete bouts and less continuous pain) and migraine variants. The dramatic indomethacin response helps distinguish hemicrania continua from other unilateral headache disorders. Indomethacin is the first-line treatment and diagnostic test. The typical approach is to start with a trial of indomethacin at doses adjusted to patient tolerance, with rapid resolution of headache confirming the diagnosis. For patients who are pregnant or lactating, indomethacin is contraindicated in the later stages of pregnancy (after 30 weeks) due to the risk of premature closure of the ductus arteriosus, and caution is advised during lactation. Alternative therapies (such as COX-2 inhibitors, topiramate, or nerve blocks) have been explored but do not typically match the efficacy of indomethacin. Option A (Indomethacin) is correct as it is the gold standard treatment for hemicrania continua. Other options (which are not listed) would not have the same diagnostic or therapeutic efficacy. 1. A complete and dramatic response to indomethacin is a diagnostic hallmark of hemicrania continua. 2. Hemicrania continua is strictly unilateral with a continuous baseline pain and periodic exacerbations. 3. In women of childbearing potential, be aware of indomethacin\u2019s contraindications later in pregnancy. Recent updates in headache management guidelines reaffirm the role of indomethacin as the treatment of choice for hemicrania continua. Newer studies continue to explore alternative agents for patients with contraindications to indomethacin, but none have yet matched its efficacy.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Percentage of migraine patients reporting the attack in ER as disabling after 24 hr after er visit or like:",
    "option_a": "10%",
    "option_b": "25%",
    "option_c": "50%",
    "option_d": "75%",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Migraine attacks are episodic headaches that can be profoundly disabling. Many studies have evaluated the impact of a migraine attack even after treatment in the emergency department (ED), and a significant proportion of patients report persistent disability 24 hours post\u2010visit. Migraine involves neurovascular dysregulation with activation of the trigeminovascular system, release of vasoactive peptides such as CGRP, and central sensitization. These processes can lead to pain amplification that persists beyond the acute phase. Patients with migraines often experience ongoing symptoms like nausea, photophobia, and functional impairment that extend well beyond the initial attack. Epidemiological studies have shown that approximately half of ED migraine patients still consider their headache disabling 24 hours later. The diagnosis of migraine is clinical. Differential diagnoses include tension-type headache, cluster headache, and secondary causes such as subarachnoid hemorrhage. A detailed history and headache diary may be used to assess pattern, duration, and associated symptoms. Acute treatment includes NSAIDs and triptans, while preventive strategies (e.g., beta-blockers, topiramate, CGRP inhibitors) are considered for frequent or prolonged disability. In the ED, early and adequate treatment is emphasized to reduce disability. For pregnancy/lactation, certain medications (e.g., acetaminophen, some NSAIDs in appropriate gestational windows) are preferred. Option A (10%) and B (25%) under\u2010estimate the disability burden, while D (75%) over\u2010estimates it. Epidemiological studies support roughly a 50% disabling rate at 24 hours after an ED visit, making Option C the most accurate. 1. Migraine attacks can have prolonged disabling effects despite ED treatment. 2. Early intervention may reduce the progression to central sensitization. 3. A headache diary is a useful clinical tool for tracking migraine frequency and disability. Recent studies and guidelines emphasize the importance of both acute and preventive treatments in reducing long\u2010term disability from migraine attacks, with data supporting that about half of ED-treated migraine patients continue to experience significant disability after 24 hours.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Unilateral headache in mid aged female associated with tearing and ptosis, what to give:",
    "option_a": "Indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "The description of a unilateral headache in a middle\u2010aged female with tearing and ptosis suggests a trigeminal autonomic cephalalgia. When a headache responds dramatically to indomethacin, it is usually an indomethacin-responsive headache disorder such as hemicrania continua (or less commonly, paroxysmal hemicrania). These headaches are thought to involve dysregulation within the trigeminal autonomic reflex. Although cluster headache is more common in men, indomethacin-responsive headaches (like hemicrania continua) occur predominantly in women and are characterized by a continuous, unilateral headache with autonomic features. Hemicrania continua presents with a constant unilateral headache with superimposed severe exacerbations, accompanied by ipsilateral cranial autonomic symptoms like lacrimation and ptosis. The hallmark of this condition is a complete response to indomethacin. Diagnosis is based on clinical history and the dramatic response to indomethacin. Differential considerations include cluster headache (which typically affects men and has circadian periodicity) and other trigeminal autonomic cephalalgias. A trial of indomethacin is often used diagnostically. Indomethacin is the treatment of choice for hemicrania continua and related indomethacin-responsive headaches. For patients who are pregnant or lactating, caution is required as indomethacin is generally avoided in the third trimester due to the risk of premature closure of the ductus arteriosus; alternative management strategies may be needed after careful risk-benefit analysis. Option A (Indomethacin) is correct because the indomethacin test is considered diagnostic for hemicrania continua. Other options, although not provided here, would include treatments more suited to other headache types (e.g., oxygen or triptans for cluster headache), which are not appropriate for an indomethacin-responsive condition. 1. The absolute indomethacin response is diagnostic for hemicrania continua. 2. Although cluster headaches share some autonomic features, their demographic and clinical pattern differ. 3. Always consider headache subtypes when autonomic features are present. Latest research reinforces that an indomethacin trial is critical in patients with unilateral headaches accompanied by autonomic symptoms, and current guidelines support its use as the first-line agent in hemicrania continua and related disorders.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Obese lady with asthma and migraine:",
    "option_a": "Topamax",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "In the context of migraine prophylaxis, patient comorbidities play an important role in the choice of medication. In an obese patient with asthma, medications that promote weight loss and avoid bronchospasm are preferred. Migraine pathophysiology involves abnormal neuronal excitability and changes in neurotransmitter systems. Prophylactic medications work by stabilizing neural circuits and preventing excessive cortical spreading depression. Topiramate, for instance, modulates sodium channels and enhances GABAergic activity. Obese patients benefit from medications that can also aid in weight reduction. Beta-blockers, another class frequently used for migraine prophylaxis, are generally contraindicated in asthma due to the risk of bronchospasm. Thus, topiramate (Topamax) becomes a preferred choice. Diagnosis of migraine is clinical, and prophylactic treatment is considered when patients have frequent or debilitating attacks. A careful review of the patient\u2019s comorbidities\u2014obesity and asthma in this case\u2014is essential for selecting an appropriate prophylactic agent. For an obese patient with asthma and migraine, topiramate (first-line in this scenario) is advantageous due to its additional effect on weight loss. However, in women of childbearing potential, topiramate requires careful counseling because of its teratogenic potential (increased risk of cleft lip/palate). Alternative options may include beta-blockers or other antiepileptics, but these must be balanced against contraindications like asthma or weight gain side effects. Option A (Topamax/Topiramate) is correct because it addresses both migraine prophylaxis and weight management without aggravating asthma. Other common migraine prophylactic agents (e.g., propranolol) would be less suitable due to their bronchoconstrictive potential in asthmatic patients, and agents like valproate could worsen weight gain. 1. Always integrate patient comorbidities when choosing prophylactic therapy for migraine. 2. Beta-blockers are contraindicated in patients with asthma. 3. Topiramate offers the dual benefit of migraine prophylaxis and weight loss, but caution is warranted in women of childbearing age. Recent guidelines and studies have solidified topiramate\u2019s role in migraine prevention, especially in patients with obesity and contraindications to beta-blockers. However, ongoing research emphasizes the need for risk-benefit discussions regarding teratogenic potential in women.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Picture of stabbing eye headache for 100 times a day, what is the ttt:",
    "option_a": "Lamictal",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "A headache described as a stabbing pain around the eye occurring very frequently (up to 100 times a day) is consistent with short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT). Lambert (Lamictal is the trade name for lamotrigine) is one of the therapies used for this condition. SUNCT is classified under the trigeminal autonomic cephalalgias. The underlying mechanism is believed to be related to abnormal activation of the trigeminal-autonomic reflex, possibly involving ion channel dysfunctions. This leads to extremely brief, severe attacks of pain with autonomic symptoms. Patients with SUNCT experience numerous, very short, severe unilateral headache episodes often associated with cranial autonomic features like eye pain, tearing, and conjunctival injection. The high frequency of attacks (up to 100 per day) fits this clinical picture. Diagnosis is largely clinical with a strong reliance on the headache attack characteristics. Differential diagnoses include cluster headache (which has longer-lasting and less frequent attacks), paroxysmal hemicrania, and trigeminal neuralgia. A careful history helps distinguish these conditions. Lamotrigine is considered a first-line prophylactic treatment for SUNCT due to its ability to reduce the frequency and intensity of attacks. In pregnancy and lactation, lamotrigine is relatively favored among antiepileptic drugs compared to others (though careful monitoring and folate supplementation are recommended), but any treatment should be tailored after a risk-benefit analysis. Option A (Lamictal, i.e. lamotrigine) is correct, as it is supported by clinical evidence for reducing attack frequency in SUNCT. Other options (not listed) may include IV lidocaine or topiramate, but lamotrigine remains a well-regarded choice for this condition. 1. SUNCT is characterized by very frequent, brief, unilateral attacks with prominent autonomic features. 2. Lamotrigine requires slow titration to minimize the risk of rash. 3. Differentiation among trigeminal autonomic cephalalgias is key to selecting the appropriate treatment. Recent case series and clinical reviews have reinforced lamotrigine\u2019s role in SUNCT management. Ongoing research is focused on better understanding the pathophysiology of SUNCT and refining treatment protocols.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Continuous headache for 3 months with some increase in a base line as an attack (side locked): -medication overuse headache",
    "option_a": "hemicrania continua",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua is a primary headache disorder characterized by a continuous, strictly unilateral headache that persists day\u2010in and day\u2010out with superimposed exacerbations. The condition is noted for its invariant side (side\u2010locked) and complete response to indomethacin. Although the precise mechanism remains uncertain, hemicrania continua is thought to involve dysfunction of the trigeminal autonomic pathways and possibly hypothalamic dysregulation. The dramatic response to indomethacin supports an inflammatory or prostaglandin\u2010mediated process distinct from other chronic daily headaches. Clinically, patients present with a continuous headache for months with episodes of worsening pain. The unilateral, side\u2010locked nature distinguishes it from many other chronic headache syndromes such as medication overuse headache, which is often less lateralized and more variable. Diagnosis is based on clinical history and the diagnostic indomethacin trial. Differential diagnoses include: medication overuse headache (typically bilateral and associated with frequent use of analgesics), chronic migraine, and cluster headache. A careful headache diary combined with response to indomethacin is diagnostic. The first\u2010line treatment is indomethacin, which is both diagnostic and therapeutic. Alternative agents have been explored for those intolerant to indomethacin. In pregnant patients, use of NSAIDs (including indomethacin) is limited especially in the third trimester due to risks such as premature closure of the ductus arteriosus; management requires a multidisciplinary discussion with obstetrics. During lactation, caution is advised since NSAIDs may pass into breast milk. Option A (hemicrania continua) is correct. The description of a continuous headache with exacerbations and a fixed unilateral location best fits hemicrania continua rather than medication overuse headache, which is typically more variable in lateralization and is linked to chronic analgesic intake. 1. Hemicrania continua is indomethacin responsive \u2013 a complete response is practically pathognomonic. 2. Its strictly unilateral, continuous nature with superimposed severe exacerbations helps differentiate it from other chronic daily headaches. 3. Always inquire about medication history to rule out medication overuse headache. Recent guidelines emphasize the indomethacin trial for a definitive diagnosis. Ongoing research aims to identify alternative treatments for patients who cannot tolerate indomethacin, highlighting the need for individualized management, especially in special populations such as pregnant or lactating women.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about ophthalmic migraine (third or six nerve palsy) asking about dx.",
    "option_a": "ophthalmic migraine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "The condition historically known as ophthalmoplegic migraine is characterized by headaches associated with paresis of one or more ocular cranial nerves. Although the term 'ophthalmic migraine' is used in some settings, modern nomenclature prefers 'recurrent painful ophthalmoplegic neuropathy' (RPON) per ICHD-3 criteria. RPON is now considered a demyelinating cranial neuropathy rather than a classic migraine variant. Inflammatory changes affecting the oculomotor (and less commonly the trochlear or abducens) nerve lead to transient ophthalmoplegia linked with headache episodes. Patients typically present with recurrent episodes of headache accompanied by ocular motor deficits \u2013 commonly a third nerve palsy with or without pupillary involvement. The recurrent nature and the association with nerve palsy are key features that distinguish this entity from typical migraine aura symptoms. The workup involves neuroimaging (MRI with contrast) to rule out compressive lesions, aneurysms, or demyelinating diseases, and to document nerve enhancement if present. Differential diagnoses include aneurysmal compression, microvascular ischemic cranial neuropathy (especially in older or diabetic patients), and myasthenia gravis; the recurrent nature coupled with MRI findings can help differentiate RPON. Management primarily includes analgesia for headache symptoms and, in some cases, corticosteroids to reduce nerve inflammation although evidence for steroids is variable. For patients who are pregnant, the use of steroids requires careful risk\u2013benefit analysis and close monitoring by obstetrics; alternative symptomatic treatments may be considered. During lactation, most corticosteroids are considered relatively safe, but consultation with a pediatric specialist is recommended. Option A (ophthalmic migraine) is intended to denote the clinical scenario of headache with ocular motor palsy. Despite the outdated nomenclature, it is acceptable in many exam settings to refer to this condition by its historical name. Modern texts would use 'ophthalmoplegic migraine' or RPON, but in the context of the question, Option A is correct. 1. Recurrent episodes of headache with ocular nerve involvement suggest RPON; always verify with imaging to exclude other causes. 2. Third nerve involvement is most common, but sixth nerve palsy can also occur. 3. The term 'ophthalmoplegic migraine' is outdated; current terminology is important for accurate diagnosis and management. Recent studies and revised ICHD-3 guidelines support the reclassification of ophthalmoplegic migraine to RPON, focusing on its inflammatory and demyelinating aspects rather than a primary migraine phenomenon. There is ongoing research into optimal management strategies including the role of steroids.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario about basilar migraine with vertigo? asking about dx:",
    "option_a": "Basilar migraine",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Basilar migraine (or basilar-type migraine) is a migraine variant in which the aura originates from the brainstem (basilar region) rather than the occipital cortex. It is characterized by a constellation of brainstem symptoms. The mechanism is thought to involve transient brainstem dysfunction possibly caused by abnormal neuronal excitability and vascular changes. Abnormal flow or hypoperfusion in the posterior circulation may play a role in producing symptoms such as vertigo, tinnitus, and ataxia. Patients with basilar migraine often present with aura symptoms including vertigo, dysarthria, ataxia, bilateral visual disturbances, and sometimes loss of consciousness, typically preceding or accompanying the headache phase. Vertigo is a common and prominent symptom in these patients. Diagnosis is clinical based on the history of typical migraine headaches accompanied by brainstem aura symptoms. Differential diagnoses include transient ischemic attacks (especially in older patients), cerebellar or brainstem infarctions, and seizure-related phenomena. Brain imaging (MRI) is often utilized to exclude structural causes. First-line treatment includes abortive therapies such as NSAIDs and, where appropriate, triptans (with caution due to their vasoconstrictive properties). Prophylactic therapies may include beta-blockers, calcium channel blockers, or anticonvulsants. In pregnancy, the use of triptans is cautiously considered based on gestational age and risk factors, and non-pharmacological measures or paracetamol and magnesium may be preferable. During lactation, many migraine abortive and prophylactic medications are used with careful monitoring. Option A (basilar migraine) is correct since the scenario describes a migraine with brainstem symptoms, notably vertigo. The presence of vertigo in a migraine context points directly to basilar migraine rather than other forms of migraine. 1. Basilar migraine is distinguished by brainstem symptoms, such as vertigo and ataxia, often bilateral in nature. 2. Typically seen in younger adults and especially in females. 3. Always rule out cerebrovascular events with appropriate imaging when brainstem symptoms occur. Recent guidelines emphasize accurate classification of migraine subtypes to tailor treatment. There is increasing evidence supporting the safety and efficacy of certain abortive agents in pregnant patients when migraine symptoms severely impact quality of life, though caution with vasoconstrictive agents remains.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "A patient who is returning from Sudan had fever, confusion, headache, gave labs and CSF result. What test should you do:",
    "option_a": "Thick blood film",
    "option_b": "MRI",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "In patients returning from malaria-endemic regions such as Sudan, the presentation of fever, confusion, and headache raises significant suspicion for cerebral malaria. Prompt identification using laboratory diagnostic tools is critical. Cerebral malaria is most commonly caused by Plasmodium falciparum. The infected erythrocytes adhere to cerebral capillaries, obstructing blood flow and releasing inflammatory mediators, leading to blood\u2013brain barrier dysfunction and neurologic symptoms. Clinically, patients present with high fever, altered mental status, headache, and sometimes seizures. Although the CSF may be relatively unremarkable, laboratory studies including a blood smear are essential to detect malarial parasites. The diagnostic workup revolves around a thick and thin blood film. The thick film is more sensitive for detecting parasites, while the thin film aids in species identification. Differential diagnoses include viral encephalitis, bacterial meningitis, and other tropical infections; the travel history and laboratory findings help differentiate these entities. Rapid initiation of antimalarial therapy is critical. First-line treatment for cerebral malaria in adults is intravenous artesunate. In pregnancy, artesunate is recommended in the second and third trimesters, although concerns exist in the first trimester where quinine may be used if artesunate is not available; lactating mothers are generally treated with similar regimens, with appropriate risk\u2013benefit counseling. Supportive care for fever, seizures, and other complications is also essential. Option A (Thick blood film) is correct. It is the most sensitive initial diagnostic test for malaria, especially in patients with neurological symptoms returning from endemic areas. MRI (Option B) is not first-line in this infectious context and would delay diagnosis. 1. A travel history is crucial in patients with febrile illnesses and neurological symptoms. 2. Cerebral malaria is a medical emergency requiring prompt diagnosis and treatment. 3. Thick blood films are the gold standard screening test for malaria, with thin films used for species differentiation. Current WHO guidelines continue to support the use of thick and thin blood films for rapid malaria diagnosis. Recent research focuses on improving rapid diagnostic testing and refining treatment protocols for cerebral malaria, particularly in vulnerable populations such as pregnant women and children.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Migraine patient with daily persistent headache, he used to take daily triptan and NSAID, what is the next management:",
    "option_a": "Aprubt discontinuation of the medications",
    "option_b": "Gradual discontinuation of the medications.",
    "option_c": "Steroid",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Medication overuse headache (MOH) is a secondary headache disorder that develops in patients with a primary headache (like migraine) who use acute headache medications (such as triptans and NSAIDs) too frequently. It transforms a typically episodic disorder into a chronic daily headache. Repeated use of acute medications is thought to induce central sensitization and alter pain modulation pathways. This may involve changes in serotonin receptor sensitivity and other neurochemical alterations leading to a lowered migraine threshold and rebound headache phenomenon. Patients who initially have migraines may start experiencing daily headaches when they overuse their symptomatic medications. The pattern of rebound or withdrawal headaches is characteristic, often presenting as a persistent, dull headache interspersed with typical migraine attacks. Diagnosis is based on a detailed history of medication use (frequency and type) and headache pattern. Differential diagnoses include chronic migraine and tension-type headache. The International Classification of Headache Disorders (ICHD-3) criteria assist in diagnosing MOH. The primary treatment is discontinuation of the overused medications. For drugs like triptans and NSAIDs, abrupt discontinuation is recommended. Although withdrawal may initially worsen headaches (a rebound phenomenon), most patients improve within a few weeks. Prophylactic therapy may be considered once the overuse headache resolves. In pregnancy and lactation, similar withdrawal principles apply, but the choice of prophylactic agents must consider fetal and neonatal safety (for example, avoiding medications contraindicated in pregnancy). Option A (Abrupt discontinuation) is the most appropriate for triptans and NSAIDs and is recommended by current guidelines. Option B (Gradual discontinuation) is more appropriate for medications like opioids or barbiturates, where abrupt cessation might lead to more severe withdrawal symptoms, but not typically for triptans/NSAIDs. Option C (Steroid) is not indicated as first-line management in MOH. 1. Educate patients about the risk of transforming episodic headaches into chronic daily headaches with frequent medication use. 2. Expect a transient worsening of headache (withdrawal headache) after abrupt cessation; supportive care is key. 3. Early recognition and intervention can prevent the development of chronic headache disorders. Recent guidelines and studies (including those from the European Federation of Neurological Societies and the American Headache Society) reinforce that for MOH related to triptans and NSAIDs, abrupt withdrawal is preferred. Research continues into bridging therapies to manage withdrawal symptoms, but the fundamental strategy remains cessation of the offending agents.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with small area of headache associated with hair loss, what is the treatment?",
    "option_a": "Gabapentin",
    "option_b": "Local anesthesia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "This scenario is suggestive of a primary headache disorder that is localized to a small, circumscribed area of the scalp. Nummular headache is characterized by a well-defined painful area, which in some cases can present with associated local skin or hair changes. The exact mechanism of nummular headache is not fully understood, but it is hypothesized to involve peripheral nerve dysfunction or localized cutaneous neuralgia. The pain is restricted to a small area, and occasionally trophic changes such as hair loss or skin changes may be observed due to chronic irritation or local neurogenic inflammation. Patients present with a small, coin-shaped area of headache typically on the scalp. The association with hair loss might be due to local trophic changes secondary to chronic pain. This is in contrast to diffuse headache syndromes where the distribution is broader. Diagnosis is primarily clinical. Evaluation includes a detailed history and physical examination. Differential diagnoses include other focal neuralgias, dermatologic conditions (e.g., alopecia areata, psoriasis), and localized scalp infections. The absence of neurological deficits and normal imaging usually supports a diagnosis of a primary headache disorder. Local treatments are often effective. Injection of local anesthetics (e.g., lidocaine) into the affected area can provide both diagnostic and therapeutic relief. While systemic treatments like gabapentin are sometimes used for neuropathic pain, local anesthesia is generally considered the first-line approach. In pregnancy and lactation, local anesthetics (such as lidocaine, which is category B) are preferred over systemic neuropathic agents which may carry more risk. Option B (Local anesthesia) is correct as local nerve blocks have shown benefit in nummular headache. Option A (Gabapentin) is less favored as the initial treatment; it is more appropriate as second-line or adjunctive therapy if local measures fail. 1. Nummular headache is rare but should be considered in patients with a small, well-defined area of scalp pain. 2. Local anesthetic injections can be both diagnostic and therapeutic. 3. Consider the benign nature of this headache when planning therapy, especially in special populations like pregnant women. Recent case reports and small series reinforce the effectiveness of local anesthetic injections for nummular headache. Although there is limited larger scale data, consensus among headache specialists supports a localized treatment approach and careful monitoring of therapeutic response.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with Trigeminal neuralgia, what is the artery usually is involved:",
    "option_a": "PCA.",
    "option_b": "AICA",
    "option_c": "SCA",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is a condition characterized by sudden, severe, electric shock-like facial pain. It is usually linked to neurovascular compression at the root entry zone of the trigeminal nerve. The most widely accepted mechanism is vascular compression of the trigeminal nerve by an aberrant or tortuous blood vessel. Repeated pulsatile compression leads to focal demyelination and abnormal electrical conduction along the nerve fibers. The Superior Cerebellar Artery (SCA) is most commonly implicated, although other vessels can occasionally be involved. Patients present with paroxysmal episodes of intense facial pain, often triggered by light touch or routine activities. The typical distribution involves the mandibular or maxillary divisions of the trigeminal nerve. High-resolution MRI with angiography aids in visualizing the vascular loop compressing the nerve. The diagnosis is primarily clinical, supported by imaging studies. Differential diagnoses include atypical facial pain, dental pain, and multiple sclerosis (especially in younger patients with bilateral symptoms). High-resolution MRI/MRA helps differentiate classic trigeminal neuralgia caused by vascular compression from secondary causes. First-line management involves pharmacologic therapy with anticonvulsants such as carbamazepine or oxcarbazepine. For patients who do not respond to medication or who experience intolerable side effects, surgical options like microvascular decompression are considered. In terms of pregnancy and lactation, the use of carbamazepine requires careful risk-benefit analysis and close monitoring due to potential teratogenicity; alternative agents may be considered if necessary. Option C (SCA) is correct, as the Superior Cerebellar Artery is the vessel most frequently involved in compressing the trigeminal nerve. Option A (PCA) and Option B (AICA) are less commonly implicated in this condition. 1. Carbamazepine remains the gold standard for the initial treatment of trigeminal neuralgia. 2. High-resolution MRI is essential in confirming the diagnosis and planning potential surgical interventions. 3. Always consider vascular compression as the underlying cause in classical trigeminal neuralgia. Recent research supports the role of high-resolution neuroimaging in confirming neurovascular compression, and advances in microsurgical techniques have improved outcomes in patients requiring microvascular decompression. Updated guidelines continue to endorse carbamazepine as first-line therapy, while emphasizing cautious use in pregnant patients.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with unilateral headache on daily basis associated with ptosis and lacrimation, Dx:",
    "option_a": "Hemicrania continua",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This case describes a unilateral headache that is present on a daily basis and is accompanied by ipsilateral autonomic symptoms such as ptosis and lacrimation. This constellation of symptoms is characteristic of trigeminal autonomic cephalalgias, with hemicrania continua being a prime example. Hemicrania continua is thought to involve dysfunction of the trigeminal-autonomic reflex and hypothalamic activation. The exact mechanism remains under investigation, but the complete response to indomethacin is a hallmark that supports a unique pathophysiological process distinct from other headaches. The condition is characterized by a continuous, unilateral headache with superimposed exacerbations, and autonomic features (such as ptosis, lacrimation, nasal congestion, or rhinorrhea) may occur during pain flares. The continuous nature of the headache differentiates it from cluster headache, which occurs in discrete bouts with pain-free intervals. Diagnosis is primarily clinical, supported by the absolute response to indomethacin \u2013 this response is both diagnostic and therapeutic. Differential diagnoses include cluster headache and paroxysmal hemicrania, but the continuous, daily nature of the pain favors hemicrania continua. The treatment of choice is a trial of indomethacin, with rapid and complete pain relief confirming the diagnosis. Indomethacin, however, must be used with caution in pregnancy (especially in the third trimester due to the risk of premature closure of the ductus arteriosus) and lactation; alternative treatments may need to be considered in these populations if indomethacin is contraindicated. Option A (Hemicrania continua) is correct given the presentation of continuous unilateral headache with ipsilateral autonomic features. Other options are not provided, but none would fit the continuous daily pattern with indomethacin responsiveness. 1. Hemicrania continua is only partially similar to other TACs and is unique in its continuous daily presentation. 2. A complete response to indomethacin is the diagnostic gold standard. 3. Awareness of indomethacin\u2019s contraindications in pregnancy is crucial when managing women of childbearing age. Recent studies and updated ICHD-3 criteria reinforce the indomethacin responsiveness of hemicrania continua. Ongoing research is evaluating alternative therapies for patients who cannot tolerate indomethacin, particularly in pregnant or lactating women.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "same scenario asking about treatment:",
    "option_a": "indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This question, although brief in its wording, refers to a headache syndrome that is classically exquisitely responsive to indomethacin \u2013 for example, paroxysmal hemicrania or hemicrania continua. These primary headache disorders are diagnosed not only by their clinical picture (unilateral headache with cranial autonomic features) but also by their absolute response to indomethacin. The underlying mechanism of these indomethacin\u2010responsive headaches remains not fully elucidated. It is thought that activation of the trigeminal autonomic pathways along with a prostaglandin\u2010mediated inflammatory component plays a central role. Indomethacin\u2019s action\u2014beyond its NSAID properties\u2014may involve modulation of nitric oxide pathways or central pain processing mechanisms that are uniquely relevant in these headache syndromes. Patients typically present with strictly unilateral headache episodes frequently accompanied by autonomic symptoms such as lacrimation, nasal congestion, or ptosis. The dramatic improvement with indomethacin is so characteristic that a therapeutic trial serves as both a treatment and a diagnostic tool. The differential diagnosis includes cluster headache, migraine, and other trigeminal autonomic cephalalgias. A trial of indomethacin that leads to complete resolution of symptoms is both supportive and, in some cases, diagnostic of paroxysmal hemicrania or hemicrania continua. First\u2010line management of an indomethacin\u2010responsive headache is to initiate indomethacin at a therapeutic dose (often starting around 25\u201350 mg three times daily and titrating upward). In patients such as pregnant women, caution is needed: indomethacin is generally avoided in the third trimester because of the risk of premature closure of the fetal ductus arteriosus; however, if the patient is not pregnant or is in a safe period, it remains the treatment of choice. Gastrointestinal prophylaxis may be considered to mitigate NSAID side effects. Option A (indomethacin) is correct because it is the hallmark treatment for indomethacin\u2010responsive headache syndromes. The other options (B, C, D) were not provided and therefore cannot be evaluated; however, in the context of the scenario, indomethacin is the correct and most evidence\u2010based choice. 1) A complete response to indomethacin is almost pathognomonic for paroxysmal hemicrania. 2) Always consider gastrointestinal and, in pregnant patients, fetal safety (especially in the third trimester) when using NSAIDs. 3) The therapeutic trial of indomethacin is both diagnostic and therapeutic. Recent reviews continue to support indomethacin as the gold\u2010standard treatment for these specific headache syndromes, and no major changes in the guidelines have been reported.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Known case of migraine female patient pregnant in her 1st trimester came to ER with headache; what is the treatment?",
    "option_a": "Triptan",
    "option_b": "Dexamethasone",
    "option_c": "Acetaminophin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "This question, although brief in its wording, refers to a headache syndrome that is classically exquisitely responsive to indomethacin \u2013 for example, paroxysmal hemicrania or hemicrania continua. These primary headache disorders are diagnosed not only by their clinical picture (unilateral headache with cranial autonomic features) but also by their absolute response to indomethacin. The underlying mechanism of these indomethacin\u2010responsive headaches remains not fully elucidated. It is thought that activation of the trigeminal autonomic pathways along with a prostaglandin\u2010mediated inflammatory component plays a central role. Indomethacin\u2019s action\u2014beyond its NSAID properties\u2014may involve modulation of nitric oxide pathways or central pain processing mechanisms that are uniquely relevant in these headache syndromes. Patients typically present with strictly unilateral headache episodes frequently accompanied by autonomic symptoms such as lacrimation, nasal congestion, or ptosis. The dramatic improvement with indomethacin is so characteristic that a therapeutic trial serves as both a treatment and a diagnostic tool. The differential diagnosis includes cluster headache, migraine, and other trigeminal autonomic cephalalgias. A trial of indomethacin that leads to complete resolution of symptoms is both supportive and, in some cases, diagnostic of paroxysmal hemicrania or hemicrania continua. First\u2010line management of an indomethacin\u2010responsive headache is to initiate indomethacin at a therapeutic dose (often starting around 25\u201350 mg three times daily and titrating upward). In patients such as pregnant women, caution is needed: indomethacin is generally avoided in the third trimester because of the risk of premature closure of the fetal ductus arteriosus; however, if the patient is not pregnant or is in a safe period, it remains the treatment of choice. Gastrointestinal prophylaxis may be considered to mitigate NSAID side effects. Option A (indomethacin) is correct because it is the hallmark treatment for indomethacin\u2010responsive headache syndromes. The other options (B, C, D) were not provided and therefore cannot be evaluated; however, in the context of the scenario, indomethacin is the correct and most evidence\u2010based choice. 1) A complete response to indomethacin is almost pathognomonic for paroxysmal hemicrania. 2) Always consider gastrointestinal and, in pregnant patients, fetal safety (especially in the third trimester) when using NSAIDs. 3) The therapeutic trial of indomethacin is both diagnostic and therapeutic. Recent reviews continue to support indomethacin as the gold\u2010standard treatment for these specific headache syndromes, and no major changes in the guidelines have been reported.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Migraine pt pregnant in her 12 weeks GA, came with status migranosis. asking about the management:",
    "option_a": "IV depakin",
    "option_b": "Dihydroegotamine",
    "option_c": "subcutaneuos sumatriptan",
    "option_d": "Steroid.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "This question, although brief in its wording, refers to a headache syndrome that is classically exquisitely responsive to indomethacin \u2013 for example, paroxysmal hemicrania or hemicrania continua. These primary headache disorders are diagnosed not only by their clinical picture (unilateral headache with cranial autonomic features) but also by their absolute response to indomethacin. The underlying mechanism of these indomethacin\u2010responsive headaches remains not fully elucidated. It is thought that activation of the trigeminal autonomic pathways along with a prostaglandin\u2010mediated inflammatory component plays a central role. Indomethacin\u2019s action\u2014beyond its NSAID properties\u2014may involve modulation of nitric oxide pathways or central pain processing mechanisms that are uniquely relevant in these headache syndromes. Patients typically present with strictly unilateral headache episodes frequently accompanied by autonomic symptoms such as lacrimation, nasal congestion, or ptosis. The dramatic improvement with indomethacin is so characteristic that a therapeutic trial serves as both a treatment and a diagnostic tool. The differential diagnosis includes cluster headache, migraine, and other trigeminal autonomic cephalalgias. A trial of indomethacin that leads to complete resolution of symptoms is both supportive and, in some cases, diagnostic of paroxysmal hemicrania or hemicrania continua. First\u2010line management of an indomethacin\u2010responsive headache is to initiate indomethacin at a therapeutic dose (often starting around 25\u201350 mg three times daily and titrating upward). In patients such as pregnant women, caution is needed: indomethacin is generally avoided in the third trimester because of the risk of premature closure of the fetal ductus arteriosus; however, if the patient is not pregnant or is in a safe period, it remains the treatment of choice. Gastrointestinal prophylaxis may be considered to mitigate NSAID side effects. Option A (indomethacin) is correct because it is the hallmark treatment for indomethacin\u2010responsive headache syndromes. The other options (B, C, D) were not provided and therefore cannot be evaluated; however, in the context of the scenario, indomethacin is the correct and most evidence\u2010based choice. 1) A complete response to indomethacin is almost pathognomonic for paroxysmal hemicrania. 2) Always consider gastrointestinal and, in pregnant patients, fetal safety (especially in the third trimester) when using NSAIDs. 3) The therapeutic trial of indomethacin is both diagnostic and therapeutic. Recent reviews continue to support indomethacin as the gold\u2010standard treatment for these specific headache syndromes, and no major changes in the guidelines have been reported.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "23 yo Female type 1 DM last year of colleague with indication for prophylaxis of her migraine what to give",
    "option_a": "Topiramate",
    "option_b": "Valproic acid, no mention of pregnancy",
    "option_c": "Propranolol",
    "option_d": "Amitriptyline",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Migraine prophylaxis is indicated when patients experience frequent or debilitating migraine attacks. In women of childbearing potential, avoiding teratogenic agents is crucial. Beta\u2010blockers, particularly propranolol, are well\u2010established first\u2010line agents for migraine prophylaxis. Migraine is believed to result from a combination of neuronal hyperexcitability, cortical spreading depression, and activation of the trigeminovascular system which leads to neurogenic inflammation. Propranolol may reduce migraine frequency by dampening sympathetic outflow and modulating neuronal excitability. This 23\u2010year-old female with type 1 diabetes needs migraine prophylaxis. Although beta\u2010blockers can mask hypoglycemia symptoms\u2014a concern in diabetic patients with type 1 DM\u2014proper patient education and frequent blood glucose monitoring can mitigate this risk. Importantly, alternatives like valproic acid and topiramate carry significant teratogenic risks, making propranolol a more appropriate choice. The diagnosis of migraine is typically clinical, based on the International Headache Society criteria. Prophylactic treatment is considered after assessing attack frequency, severity, and impact on quality of life. Differential diagnoses include tension-type headaches and secondary headache disorders. According to the latest evidence and guidelines, beta\u2010blockers such as propranolol are first\u2010line agents for migraine prophylaxis. In patients of reproductive age, the teratogenic potentials of drugs like valproic acid and topiramate necessitate their avoidance. Even though propranolol is a nonselective beta\u2010blocker and may obscure hypoglycemic symptoms in diabetic patients, with diligent monitoring and patient education, its use remains acceptable. In pregnancy and lactation, propranolol is classified as Category C but is used when the benefits outweigh the potential risks, making it a viable option with appropriate oversight. Option A (Topiramate) is effective for migraine prophylaxis but carries a risk for cleft lip and palate and other congenital malformations. Option B (Valproic acid) is highly teratogenic and contraindicated in women of childbearing potential. Option C (Propranolol) is supported by strong evidence as a first\u2010line prophylactic agent and, with appropriate precautions, can be used safely in diabetic patients. Option D (Amitriptyline) is an alternative but is generally considered second-line due to side effects such as sedation and weight gain. In young women, especially those who may become pregnant, always avoid medications with significant teratogenic risks. For migraine prophylaxis, propranolol is favored provided that the patient\u2019s diabetic status is managed by educating her about the potential for hypoglycemia masking and ensuring regular blood sugar monitoring. Recent guidelines and meta-analyses endorse beta-blockers, including propranolol, as effective and generally safe for migraine prophylaxis. The accumulated evidence also emphasizes the need to avoid teratogens like valproate and topiramate in women of childbearing age. With close monitoring for hypoglycemia in diabetic patients, propranolol remains the optimal choice.",
    "exam_year": "2022",
    "exam_type": "Part II"
  },
  {
    "question": "Female pregnant with status migrainosus in 3rd trimester",
    "option_a": "Methylprednisolone",
    "option_b": "Intranasal DHE",
    "option_c": "Valproic acid",
    "option_d": "SC sumatriptan",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Headache",
    "explanation": "Status migrainosus is a severe, prolonged migraine attack (lasting more than 72 hours) that requires prompt and effective abortive therapy. In a pregnant patient, especially in the 3rd trimester, treatment choices must balance rapid relief with fetal safety. Migraines involve activation of the trigeminovascular system with release of vasoactive peptides, resulting in inflammation and vasodilation. Hormonal fluctuations in pregnancy can predispose to more severe or prolonged attacks. In status migrainosus, sustained neuronal hyperexcitability and prolonged activation of these pathways occur. Clinically, patients present with severe, lasting headache often accompanied by nausea, photophobia, and phonophobia. In pregnant patients, it is essential to choose a treatment that relieves symptoms quickly while avoiding drugs that may harm the fetus or induce uterine contractions. Diagnosis is based on clinical history and exclusion of secondary causes (e.g., preeclampsia, cerebral venous sinus thrombosis). Differential diagnoses include other primary headache disorders and intracranial pathologies, which are sorted out with careful history, examination, and appropriate imaging if indicated. Management in pregnancy prioritizes medications with proven safety data. First\u2010line therapy for severe acute migraine in pregnancy is non\u2010pharmacologic measures with analgesics. When abortive therapy is required, subcutaneous (SC) sumatriptan is generally considered the best option due to its rapid onset and accumulation of safety data in pregnancy. Corticosteroids like methylprednisolone are usually reserved as adjunctive therapy in refractory cases and are not first\u2010line due to potential side effects. In the third trimester, NSAIDs and ergot derivatives (like intranasal DHE) are contraindicated because of risks of premature ductus arteriosus closure and uterine vasoconstriction. Option A (Methylprednisolone) may offer some benefit in refractory cases but is not the first-line acute treatment; Option B (Intranasal DHE) is contraindicated in pregnancy because of its potent vasoconstrictor and uterotonic properties; Option C (Valproic acid) is highly teratogenic and absolutely contraindicated; Option D (SC Sumatriptan) is the preferred acute abortive treatment in pregnancy and is supported by observational safety data. \u2022 SC Sumatriptan has the most robust evidence among triptans for use in pregnancy.  \u2022 Ergot derivatives are contraindicated in pregnant patients due to their uterine vasoconstrictive effects. Recent guidelines and observational studies support the use of SC sumatriptan for acute migraine in pregnancy when needed, emphasizing the importance of a risk\u2013benefit analysis. Corticosteroids remain a secondary option for refractory cases rather than first-line therapy.",
    "exam_year": "2022",
    "exam_type": "Part II"
  }
]